Media coverage about Shire (NASDAQ:SHPG) has trended somewhat positive on Monday, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Shire earned a daily sentiment score of 0.03 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 47.8246290862579 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern’s scoring:
- Shire (SHPG) Upgraded at Zacks Investment Research (americanbankingnews.com)
- Shire (SHPG) Given a $186.00 Price Target by Royal Bank of Canada Analysts (americanbankingnews.com)
- Resident feedback from Market Community Scorecard to inform Shire of Murray on direction over next 10 years (communitynews.com.au)
- Sweet Enough? Takeda Raises, Adds Cash To Shire Offer (scrip.pharmaintelligence.informa.com)
- Takeda ups its offer for Shire (pharmatimes.com)
A number of analysts have recently issued reports on the company. Zacks Investment Research upgraded Shire from a “sell” rating to a “hold” rating in a report on Monday. BidaskClub cut Shire from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. Cantor Fitzgerald set a $222.00 target price on Shire and gave the stock a “buy” rating in a report on Monday, April 9th. B. Riley boosted their target price on Shire to $200.00 and gave the stock a “buy” rating in a report on Thursday. Finally, ValuEngine cut Shire from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Nine investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $205.00.
Shire (NASDAQ:SHPG) last released its quarterly earnings results on Thursday, April 26th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.58 by ($0.21). Shire had a return on equity of 14.19% and a net margin of 28.17%. sell-side analysts anticipate that Shire will post 15.21 EPS for the current fiscal year.
The business also recently declared a semiannual dividend, which will be paid on Tuesday, April 24th. Shareholders of record on Friday, March 9th will be issued a $0.8937 dividend. This represents a yield of 1.33%. The ex-dividend date is Thursday, March 8th. This is a boost from Shire’s previous semiannual dividend of $0.15. Shire’s dividend payout ratio is currently 6.93%.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.